CN104211775A - 细菌群体感应的抗体介导性破坏 - Google Patents

细菌群体感应的抗体介导性破坏 Download PDF

Info

Publication number
CN104211775A
CN104211775A CN201410258364.XA CN201410258364A CN104211775A CN 104211775 A CN104211775 A CN 104211775A CN 201410258364 A CN201410258364 A CN 201410258364A CN 104211775 A CN104211775 A CN 104211775A
Authority
CN
China
Prior art keywords
seq
amino acid
aureus
peptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410258364.XA
Other languages
English (en)
Chinese (zh)
Inventor
金·D·扬达
贡纳尔·F·考夫曼
荣古克·帕克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN104211775A publication Critical patent/CN104211775A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201410258364.XA 2007-10-25 2008-10-24 细菌群体感应的抗体介导性破坏 Pending CN104211775A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98259307P 2007-10-25 2007-10-25
US60/982,593 2007-10-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880113179.4A Division CN101835484B (zh) 2007-10-25 2008-10-24 细菌群体感应的抗体介导性破坏

Publications (1)

Publication Number Publication Date
CN104211775A true CN104211775A (zh) 2014-12-17

Family

ID=40580303

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410258364.XA Pending CN104211775A (zh) 2007-10-25 2008-10-24 细菌群体感应的抗体介导性破坏
CN200880113179.4A Expired - Fee Related CN101835484B (zh) 2007-10-25 2008-10-24 细菌群体感应的抗体介导性破坏

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880113179.4A Expired - Fee Related CN101835484B (zh) 2007-10-25 2008-10-24 细菌群体感应的抗体介导性破坏

Country Status (9)

Country Link
US (2) US9394371B2 (https=)
EP (2) EP2842565B1 (https=)
JP (3) JP5581490B2 (https=)
KR (1) KR101557173B1 (https=)
CN (2) CN104211775A (https=)
AU (1) AU2008317331B2 (https=)
CA (2) CA2975568A1 (https=)
ES (1) ES2603061T3 (https=)
WO (1) WO2009055054A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111573853A (zh) * 2020-05-29 2020-08-25 南京大学 一种削减生物法处理废水毒性的方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928543A1 (en) 2012-10-26 2014-05-01 Gunnar F. Kaufmann Anti-infective binding proteins that bind aip2
DE102013211850A1 (de) * 2013-06-21 2014-12-24 Gilupi Gmbh Schnelltest zum Nachweisen von Erregermaterial, insbesondere zur Unterstützung der Diagnose einer Sepsis, sowie Kit und Vorrichtung zur Durchführung eines Sepsistests
WO2015015003A1 (en) * 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
JP2017509587A (ja) 2013-12-27 2017-04-06 ノーバス・インターナショナル・インコーポレイテッドＮｏｖｕｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ，Ｉｎｃ． エトキシル化界面活性剤
EP3981874A1 (en) 2014-01-29 2022-04-13 KM Biologics Co., Ltd. Anti-transthyretin human antibody
EP3101131B1 (en) 2014-01-29 2020-08-19 KM Biologics Co., Ltd. Anti-transthyretin humanized antibody
EP3103808B1 (en) 2014-02-07 2018-08-22 Miyarisan Pharmaceutical Co., Ltd. Peptide having activity of inhibiting production of toxin by bacterium belonging to genus clostridium
US10821167B2 (en) * 2016-02-02 2020-11-03 Unm Rainforest Innovations VLP-based vaccines for targeting Staphylococcus aureus secreted virulence factors
WO2018031730A2 (en) * 2016-08-11 2018-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
JP7128829B2 (ja) 2017-02-17 2022-08-31 マップ バイオファーマシューティカル、インコーポレイテッド エボラ感染症の処置用のモノクローナル抗体およびカクテル
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
JP7373176B2 (ja) * 2017-08-31 2023-11-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚の酵素活性を制御する分子的細菌療法
AU2018331517B2 (en) 2017-09-15 2024-10-03 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
US10774135B2 (en) 2017-12-22 2020-09-15 Sorrento Therapeutics, Inc. Variant antibodies that bind AIP2
CN111684019B (zh) 2018-02-13 2022-08-02 住友化学株式会社 组合物及成形体
CA3150161A1 (en) 2019-08-13 2021-02-18 Darlene E. MCCORD Non-activated, amorphous, ph neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals
EP4423197A4 (en) 2021-10-25 2025-08-27 Darlene E Mccord COATED MEDICINAL CLAY COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND DELIVERY OF CATION SOURCES AND METHODS OF USE THEREOF

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078207A1 (en) * 2001-09-11 2003-04-24 Sichuan Ntc Holdings Limited Engineered antibiotic peptides and the preparation thereof
WO2004014423A1 (en) * 2002-08-13 2004-02-19 Haptogen Ltd Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT932613E (pt) * 1996-05-22 2005-06-30 Univ New York Expressao de bloqueio de factoes de virulencia em s. aureus
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU2001259734A1 (en) 2000-05-10 2001-11-20 Princeton University Compounds and methods for regulating bacterial growth and pathogenesis
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US6463632B2 (en) * 2001-02-07 2002-10-15 Hans Oetiker Ag Maschinen-Und Apparatefabrik Guide arrangement for tightening tool emplacement in hose clamps provided with plastically deformable ears

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078207A1 (en) * 2001-09-11 2003-04-24 Sichuan Ntc Holdings Limited Engineered antibiotic peptides and the preparation thereof
WO2004014423A1 (en) * 2002-08-13 2004-02-19 Haptogen Ltd Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUNGUK PARK等: "Infection control by antibody disruption of bacterial quorum sensing signaling", 《CHEMISTRY & BIOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111573853A (zh) * 2020-05-29 2020-08-25 南京大学 一种削减生物法处理废水毒性的方法
CN111573853B (zh) * 2020-05-29 2020-11-20 南京大学 一种削减生物法处理废水毒性的方法

Also Published As

Publication number Publication date
CA2975568A1 (en) 2009-04-30
CN101835484A (zh) 2010-09-15
JP2018021021A (ja) 2018-02-08
JP6183910B2 (ja) 2017-08-23
WO2009055054A3 (en) 2009-09-03
CN101835484B (zh) 2014-07-16
KR20100102100A (ko) 2010-09-20
US20100291093A1 (en) 2010-11-18
EP2211889A2 (en) 2010-08-04
ES2603061T3 (es) 2017-02-23
US20170043020A1 (en) 2017-02-16
KR101557173B1 (ko) 2015-10-05
CA2703133A1 (en) 2009-04-30
EP2211889A4 (en) 2012-01-11
EP2211889B1 (en) 2014-08-20
EP2842565B1 (en) 2016-08-24
AU2008317331B2 (en) 2013-08-29
JP2014221774A (ja) 2014-11-27
US9394371B2 (en) 2016-07-19
JP5581490B2 (ja) 2014-09-03
EP2842565A1 (en) 2015-03-04
CA2703133C (en) 2017-09-19
WO2009055054A2 (en) 2009-04-30
AU2008317331A1 (en) 2009-04-30
JP2011500814A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
CN101835484B (zh) 细菌群体感应的抗体介导性破坏
US20230382980A1 (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
US7045131B2 (en) Staphylococcal immunotherapeutics via donor selection and donor stimulation
AU2002322127B2 (en) Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
AU2002256985B8 (en) Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
JP2011046705A (ja) 抗ラクトンシグナル分子抗体または抗ラクトン由来シグナル分子抗体による感染性細菌症の治療のための方法
US20020169288A1 (en) Collagen-binding adhesin from staphylococcus epidermidis and method of use
AU2005251535A1 (en) Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141217

RJ01 Rejection of invention patent application after publication